Results 31 to 40 of about 13,861 (172)

Serum Levels of Asprosin, a Novel Adipokine, Are Significantly Lowered in Patients with Acromegaly

International Journal of Endocrinology, 2020
Background. Asprosin is a novel identified adipokine secreted mainly by white adipose tissue, which is elevated in metabolic diseases such as diabetes and obesity.
Xiaoan Ke, Lian Duan, Fengying Gong, Yuelun Zhang, Kan Deng, Yong Yao, Linjie Wang, Hui Pan, Huijuan Zhu   +8 more
doaj   +1 more source

Polycystic ovary syndrome preceding the diagnosis of acromegaly: a retrospective study in 97 reproductive-aged women

Reproductive Biology and Endocrinology, 2023
Background Acromegaly is a disease of growth hormone excess that results in enlargement of extremities, abnormal glucose and lipid metabolism, and gonadal disruption. Manifestations of the disease are insidious and typically lead to a diagnostic delay of
Anamil M. Khiyami, Tahereh Orouji Jokar, Hussein M. Abdallah, Paul A. Gardner, Georgios A. Zenonos, Aaron K. Styer, Pouneh K. Fazeli   +6 more
doaj   +1 more source

Clinical characteristics and efficacy of acromegaly treatment in the Udmurt Republic

Alʹmanah Kliničeskoj Mediciny, 2022
Background: Acromegaly is a severe neuroendocrine disorder caused by chronic overproduction of growth hormone and insulin-like growth factor 1 and associated with a variety of clinical manifestations, debilitating complications and progressive disability,
Guzel M. Nurullina, Guzyal I. Akhmadullina, Irina S. Maslova, Alexandra R. Nikolaeva   +3 more
doaj   +1 more source

Insulin Resistance: An Update on Biochemical and Pathophysiological Mechanisms and Impact on Various Diseases

iNew Medicine, EarlyView.
ABSTRACT Insulin resistance is the biological phenomenon in which the human body's normal response to the metabolic hormone insulin is compromised. Insulin is a regulator of most of the essential metabolic steps in the body that control energy homoeostasis, so dysregulation leads to multiple diverse human diseases including, most prominently, Type 2 ...
Peter J. Little, Stefan Offermanns, Haaglim Cho, Zhiping Liu, Pinglian Yang, Qiaozhu Su, Henry Wade, Wah Yang, Danielle Kamato, Neale Cohen, Alex Bobik, Iqra Ilyas, Suowen Xu   +12 more
wiley   +1 more source

Acromegaly with metastatic renal cell carcinoma: Lung, gluteal and scapular metastasis

Medicine Science, 2018
The association between acromegaly and increased incidence of malignancy has been reported due to high GH and IGF levels. Although the incidence of all malignancies increases in patients with acromegaly, renal cell carcinoma (RCC) has been rarely ...
Ziynet Alphan Uc, Ozgur Demir, Suheyla Gorar, Sevim Gullu   +3 more
doaj   +1 more source

Acromegaly Presenting With Cricoarytenoid Joint Arthropathy

The Laryngoscope, EarlyView.
Excess growth hormone in acromegaly induces characteristic acral and soft tissue overgrowth (particularly in the face and hands), arthropathies, as well as cardiovascular and metabolic complications. Similar proliferative changes can occur in the larynx, where hypertrophy of the arytenoid and cricoid cartilages may impair vocal fold mobility.
Samantha Salvi Cruz, Riley Larkin, Ioan Lina, Alexander Gelbard   +3 more
wiley   +1 more source

Incidence of bronchiectasis in patients with acromegaly: a cohort study

Frontiers in Endocrinology
ObjectiveAssociations between acromegaly and several respiratory diseases, such as obstructive lung disease or sleep apnea, have been suggested, but the relationship between bronchiectasis and acromegaly is unclear.
Hyun-Il Gil, Kyungdo Han, Sangmo Hong, Cheol-Young Park   +3 more
doaj   +1 more source

Luteinizing hormone receptor knockout mouse: What has it taught us?

Andrology, EarlyView.
Abstract Luteinizing hormone (LH), along with its agonist choriongonadotropin (hCG) in humans, is the key hormone responsible for the tropic regulation of the gonadal function. LH and hCG act through their cognate receptor, the luteinizing hormone/choriongonadotropin receptor (LHCGR; more appropriately LHR in rodents lacking CG), located in the testis ...
Ilpo T. Huhtaniemi
wiley   +1 more source

Guidelines on diagnostics and treatment of acromegaly (draft)

Ожирение и метаболизм
We recommend acromegaly to be ruled in all patients with characteristic changes in appearance (A3). In all patients without characteristic changes in appearance, we recommend to rule out acromegaly, if several clinical signs suspicious for acromegaly are
E. G. Przhiyalkovskaya, N. G. Mokrysheva, E. A. Troshina, G. A. Melnichenko, I. I. Dedov, M. B. Antsiferov, L. I. Astafieva, T. P. Bardymova, Zh. E. Belaya, G. R. Vagapova, S. Yu. Vorotnikova, A. Yu. Grigoriev, E. N. Grineva, L. K. Dzeranova, I. A. Ilovaiskaya, P. L. Kalinin, A. M. Lapshina, A. S. Lutsenko, E. O. Mamedova, E. I. Marova, M. A. Perepelova, E. A. Pigarova, V. S. Pronin, L. Ya. Rozhinskaya, Yu. Yu. Trunin, A. S. Shutova   +25 more
doaj   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source